These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17491201)

  • 21. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM; Ordóñez-Llanos J; Jorba O; Pérez A
    Metabolism; 2004 Nov; 53(11):1516. PubMed ID: 15558848
    [No Abstract]   [Full Text] [Related]  

  • 26. [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
    MMW Fortschr Med; 2005 Aug; 147(33-34):51. PubMed ID: 16138641
    [No Abstract]   [Full Text] [Related]  

  • 27. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
    Liguori E; Sarcinella R
    Minerva Cardioangiol; 1998 Sep; 46(9):317-8. PubMed ID: 10021861
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E; Harats D; Gavish D
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 32. [Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
    MMW Fortschr Med; 2005 Mar; 147(12):4. PubMed ID: 15832778
    [No Abstract]   [Full Text] [Related]  

  • 33. [Lowering of cholesterol. What role is played by the choice of statins?].
    März W
    MMW Fortschr Med; 2004 Sep; 146(35-36):55. PubMed ID: 15540544
    [No Abstract]   [Full Text] [Related]  

  • 34. Atorvastatin versus simvastatin.
    Calder RA
    Am J Cardiol; 1997 Dec; 80(12):1646. PubMed ID: 9416964
    [No Abstract]   [Full Text] [Related]  

  • 35. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Am J Cardiol; 2004 Jan; 93(1):104-7. PubMed ID: 14697480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
    MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655
    [No Abstract]   [Full Text] [Related]  

  • 37. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 38. [The 10-minute consultation: accidently discovered hypercholesteremia].
    Tatò F
    MMW Fortschr Med; 2004 Sep; 146(35-36):59-60. PubMed ID: 15540545
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 40. [Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
    Klose G
    MMW Fortschr Med; 2004 Jun; 146(26):14. PubMed ID: 15529683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.